MX2015008034A - Benzazepinas como ligandos de receptor de serotonina 5-ht2c y usos de las mismas. - Google Patents

Benzazepinas como ligandos de receptor de serotonina 5-ht2c y usos de las mismas.

Info

Publication number
MX2015008034A
MX2015008034A MX2015008034A MX2015008034A MX2015008034A MX 2015008034 A MX2015008034 A MX 2015008034A MX 2015008034 A MX2015008034 A MX 2015008034A MX 2015008034 A MX2015008034 A MX 2015008034A MX 2015008034 A MX2015008034 A MX 2015008034A
Authority
MX
Mexico
Prior art keywords
compounds
serotonin
benzazepines
receptor ligands
ht2c
Prior art date
Application number
MX2015008034A
Other languages
English (en)
Inventor
Mike Robarge
John Harrington
David Gerrish
John Mecom
Original Assignee
Abt Holding Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abt Holding Co filed Critical Abt Holding Co
Publication of MX2015008034A publication Critical patent/MX2015008034A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/32—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems containing carbocyclic rings other than six-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Addiction (AREA)
  • Child & Adolescent Psychology (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epidemiology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)

Abstract

La presente invención se refiere de manera general a una serie de compuestos, a composiciones farmacéuticas que contienen los compuestos, y al uso de los compuestos y composiciones como agentes terapéuticos; más específicamente, los compuestos de la presente invención son compuestos de benzazepina; estos compuestos son ligandos de receptor de serotonina (5-HT2C) y son útiles para tratar enfermedades, trastornos y condiciones en donde se desee la modulación de la actividad de los receptores de serotonina (5-HT2C) (por ejemplo, adicción, ansiedad, depresión, obesidad y otros).
MX2015008034A 2012-12-21 2013-12-23 Benzazepinas como ligandos de receptor de serotonina 5-ht2c y usos de las mismas. MX2015008034A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261745241P 2012-12-21 2012-12-21
PCT/US2013/077501 WO2014100815A2 (en) 2012-12-21 2013-12-23 Benzazepines as serotonin 5-ht2c receptor ligands and uses thereof

Publications (1)

Publication Number Publication Date
MX2015008034A true MX2015008034A (es) 2016-03-07

Family

ID=50979422

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015008034A MX2015008034A (es) 2012-12-21 2013-12-23 Benzazepinas como ligandos de receptor de serotonina 5-ht2c y usos de las mismas.

Country Status (14)

Country Link
US (1) US9284277B2 (es)
EP (1) EP2938345B1 (es)
JP (1) JP2016503808A (es)
KR (1) KR20150108840A (es)
CN (1) CN105101967B (es)
AU (1) AU2013364022A1 (es)
BR (1) BR112015014674A2 (es)
CA (1) CA2894552A1 (es)
EA (1) EA026397B1 (es)
IL (1) IL239206B (es)
MX (1) MX2015008034A (es)
SG (1) SG11201504749TA (es)
WO (1) WO2014100815A2 (es)
ZA (1) ZA201503955B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015066344A1 (en) 2013-11-01 2015-05-07 Arena Pharmaceuticals, Inc. 5-ht2c receptor agonists and compositions and methods of use
CN105859536B (zh) * 2016-05-06 2018-08-14 蚌埠中实化学技术有限公司 一种3,4-二氟苯甲醛的制备方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4255445A (en) * 1980-03-07 1981-03-10 Smithkline Corporation 8-Hydroxy-6,7-(2-methyl-2,3-dihydrofuro)-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepines
ZA821020B (en) 1981-02-18 1983-10-26 Thomae Gmbh Dr K Azepine derivatives, process for their preparation and pharmaceutical compositions thereof
DE3230696A1 (de) 1982-08-18 1984-02-23 Dr. Karl Thomae Gmbh, 7950 Biberach Neue thieno-thiazol-derivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
GB8800891D0 (en) 1988-01-15 1988-02-17 Lilly Industries Ltd Pharmaceutical compounds
GB9025890D0 (en) 1990-11-28 1991-01-09 Lilly Industries Ltd Pharmaceutical compounds
US5532240A (en) 1991-12-26 1996-07-02 Yoshitomi Pharmaceutical Industries, Ltd. Condensed thiophene compound and pharmaceutical use thereof
KR930703327A (ko) 1991-12-26 1993-11-29 고야 다다시 축합형 티오펜 화합물 및 그의 의약용도
DK26793D0 (da) * 1993-03-10 1993-03-10 Novo Nordisk As Benzofuranyl- eller dihydrobenzofuranyl-substituerede tricycliske benzazepiner, der anvendelse og fremstilling
WO1996011201A1 (en) 1994-10-11 1996-04-18 Takeda Chemical Industries, Ltd. Substituted heterobicyclic alkyl amines and their use as squalene oxide cyclase inhibitors
WO2002034760A2 (en) * 2000-10-23 2002-05-02 Smithkline Beecham Corporation Compounds and methods
WO2004024065A2 (en) 2002-09-12 2004-03-25 Merck & Co., Inc. Substituted bicyclic thiophene derivatives, compostions containing such compounds and methods of use
CN101792417A (zh) 2003-06-17 2010-08-04 艾尼纳制药公司 用于治疗5ht2c受体相关疾病的苯并氮杂卓衍生物
EP2189448B1 (en) 2003-06-17 2014-01-29 Arena Pharmaceuticals, Inc. Processes for the Separation of 3-Benzazepine Racemates
ATE420881T1 (de) 2003-09-17 2009-01-15 Janssen Pharmaceutica Nv Kondensierte heterocyclische verbindungen als modulatoren des serotoninrezeptors
US20070275949A1 (en) 2003-10-22 2007-11-29 Arena Pharmaceuticals, Inc. Benzazepine Derivatives and Methods of Prophylaxis or Treatment of 5Ht2C Receptor Associated Diseases
US20080009478A1 (en) 2003-10-22 2008-01-10 Arena Pharmaceuticals, Inc. Benzazepine Derivatives and Methods of Prophylaxis or Treatment of 5Ht2c Receptor Associated Diseases
NZ550891A (en) 2004-06-30 2009-10-30 Athersys Inc Substituted azepine derivatives as serotonin receptor modulators
EP2421870B1 (en) 2009-04-23 2016-03-09 AbbVie Inc. Modulators of 5-ht receptors and methods of use thereof

Also Published As

Publication number Publication date
EP2938345A4 (en) 2016-10-05
WO2014100815A3 (en) 2014-08-21
EP2938345B1 (en) 2018-08-22
IL239206A0 (en) 2015-07-30
CA2894552A1 (en) 2014-06-26
EP2938345A2 (en) 2015-11-04
KR20150108840A (ko) 2015-09-30
IL239206B (en) 2018-12-31
JP2016503808A (ja) 2016-02-08
EA201591199A1 (ru) 2015-10-30
CN105101967B (zh) 2019-06-28
ZA201503955B (en) 2016-05-25
EA026397B1 (ru) 2017-04-28
WO2014100815A2 (en) 2014-06-26
US9284277B2 (en) 2016-03-15
SG11201504749TA (en) 2015-07-30
US20140194411A1 (en) 2014-07-10
AU2013364022A1 (en) 2015-07-02
BR112015014674A2 (pt) 2017-07-11
CN105101967A (zh) 2015-11-25

Similar Documents

Publication Publication Date Title
GEP201706638B (en) Benzothiophene derivatives and compositions thereof as selective estrogen receptor degraders
TW200738732A (en) Thiophenyl and pyrrolyl azepines as serotonin 5-HT2C receptor ligands and uses thereof
UY32629A (es) Compuestos antivirales, composiciones y uso para la manufactura de un medicamento para el tratamiento de trastornos asociados con hepatitis c.
TN2014000030A1 (en) Tetrahydropyrido-pyridine and tetrahydropyrido-pyrimidine compounds and use thereof as c5a receptor modulators
MX2010003949A (es) N-fenil-bipirrolidina carboxamidas sustituidas y uso terapeutico de las mismas.
TW200611906A (en) Substituted azepine derivatives as serotonin receptor modulators
EA201201541A1 (ru) НОВЫЕ ПРОИЗВОДНЫЕ ЦИКЛОГЕКСИЛАМИНА, ОБЛАДАЮЩИЕ АГОНИСТИЧЕСКОЙ АКТИВНОСТЬЮ ПО ОТНОШЕНИЮ К β2 АДРЕНЕРГИЧЕСКОМУ РЕЦЕПТОРУ И АНТАГОНИСТИЧЕСКОЙ АКТИВНОСТЬЮ ПО ОТНОШЕНИЮ К M3 МУСКАРИНОВОМУ РЕЦЕПТОРУ
EA201400569A1 (ru) Новые производные циклогексиламина, обладающие агонистической активностью по отношению к бета-2 адренергическому рецептору и антагонистической активностью по отношению к мускариновому рецептору м3
TW200619196A (en) Tricyclic indeno-pyrrole derivatives as serotonin receptor modulators
EA201400567A1 (ru) НОВЫЕ ПРОИЗВОДНЫЕ ЦИКЛОГЕКСИЛАМИНА, ОБЛАДАЮЩИЕ АГОНИСТИЧЕСКОЙ АКТИВНОСТЬЮ ПО ОТНОШЕНИЮ К β2 АДРЕНЕРГИЧЕСКОМУ РЕЦЕПТОРУ И АНТАГОНИСТИЧЕСКОЙ АКТИВНОСТЬЮ ПО ОТНОШЕНИЮ К МУСКАРИНОВОМУ РЕЦЕПТОРУ М3
MX2014000964A (es) Derivados aza heterociclicos sustituidos.
EA201500651A1 (ru) НОВЫЕ ПРОИЗВОДНЫЕ ЦИКЛОГЕКСИЛ- И ХИНУКЛИДИНИЛКАРБАМАТА, ОБЛАДАЮЩИЕ АГОНИСТИЧЕСКОЙ АКТИВНОСТЬЮ ПО ОТНОШЕНИЮ К β2 АДРЕНЕРГИЧЕСКОМУ РЕЦЕПТОРУ И АНТАГОНИСТИЧЕСКОЙ АКТИВНОСТЬЮ ПО ОТНОШЕНИЮ К МУСКАРИНОВОМУ РЕЦЕПТОРУ М3
PH12014501195A1 (en) Novel 2h-indazoles as ep2, receptor antagonists
MX2010004003A (es) N-fenil-pirrolidinilmetlipirrolidin amidas sustituidas y uso terapeutico de las mismas.
PH12015500398B1 (en) Ethynyl derivatives as modulators of mglur5 receptor activity
MY183111A (en) 3-(heteroaryl-amino)-1,2,3,4-tetrahydro-9h-carbazole derivatives and their use as prostaglandin d2 receptor modulators
MX357504B (es) Derivado de feniltriazol y su uso para modular complejo del receptor gabaa.
MX2015008733A (es) Derivados de 1,2,3-triazol-4-amina para el tratamiento de enfermedades y transtornos relacionados con receptores sigma.
PH12015502692B1 (en) Ethynyl derivatives as metabotropic glutamate receptor antagonists
MX2014000963A (es) Derivados de carboxamida y urea aromaticos biciclicos sustituidos como ligandos del receptor de vanilloide.
MX2015008034A (es) Benzazepinas como ligandos de receptor de serotonina 5-ht2c y usos de las mismas.
PH12015500496B1 (en) Ethynyl derivatives as modulators of mglur5 receptor activity
PH12015500346A1 (en) Ethynyl derivatives as modulators of mglur5 receptor activity
MX2013001988A (es) Compuestos de heterociclilo comoligandos del receptor h3 de la histamina
MX2015005312A (es) Derivados de 1h-indazol-3-carboxamida y uso de los mismos como antagonistas de p2y12.